PMID- 12873589
OWN - NLM
STAT- MEDLINE
DCOM- 20030904
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 98
IP  - 7
DP  - 2003 Jul
TI  - HLA class I B44 is associated with sustained response to interferon + ribavirin 
      therapy in patients with chronic hepatitis C.
PG  - 1621-6
AB  - OBJECTIVE: The aim of this study was to assess the influence of host genetic 
      factors on response to combination therapy for chronic hepatitis C infection. 
      METHODS: Patients with biopsy-proved chronic hepatitis C infection were treated 
      with interferon alone (n = 143) or combined therapy of interferon + ribavarin (n 
      = 105; 46 treatment naive, 59 relapsers). Human leukocyte antigen (HLA) class I 
      was determined by microlymphocytotoxicity and class II by polymerase chain 
      reaction-single specific oligonucleotide. The two biallelic tumor necrosis 
      factor-alpha promoter polymorphisms were studied by a polymerase chain 
      reaction-amplification refractory mutation system. Other variables measured were 
      viral genotype, hepatitis C virus RNA load, liver function tests, and ferritin 
      concentration. RESULTS: Univariate analysis indicated that patients bearing HLA 
      B44+, DRB1*03, infected by genotype non-1, with higher concentrations of 
      transaminases and shorter duration of infection showed a higher sustained 
      response (SR) rate than those on combination therapy. HLA class II and TNF-alpha 
      promoter polymorphisms were not related to SR. In multivariate analysis, non-1 
      genotype (OR 2.42, 95% CI 1.12-5.55, p = 0.026) and HLA B44+ (OR 4.84, 95% CI 
      1.3-17.8, p = 0.017) were the independent variables associated with SR. However, 
      HLA B44+ was not associated with SR in patients treated with interferon alone. 
      CONCLUSIONS: HLA class I B44 is related to a higher rate of SR in combination 
      therapy but not in interferon monotherapy, whereas HLA class II, tumor necrosis 
      factor-alpha -238A or -308A seem not to influence response to the antiviral 
      therapy. These findings may be of value in therapy selection for hepatitis 
      C-infected patients.
FAU - Romero-Gomez, Manuel
AU  - Romero-Gomez M
AD  - Hepatology Unit, Hospital Universitario de Valme, Seville, Spain.
FAU - Gonzalez-Escribano, Maria Francisca
AU  - Gonzalez-Escribano MF
FAU - Torres, Belen
AU  - Torres B
FAU - Barroso, Natalia
AU  - Barroso N
FAU - Montes-Cano, Marco Antonio
AU  - Montes-Cano MA
FAU - Sanchez-Munoz, Diego
AU  - Sanchez-Munoz D
FAU - Nunez-Roldan, Antonio
AU  - Nunez-Roldan A
FAU - Aguilar-Reina, Jose
AU  - Aguilar-Reina J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B44 Antigen)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Aging
MH  - Alleles
MH  - Antiviral Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - HLA-B Antigens/*analysis
MH  - HLA-B44 Antigen
MH  - Hepacivirus/genetics
MH  - Hepatitis C, Chronic/*drug therapy/*immunology/virology
MH  - Histocompatibility Antigens Class II/analysis
MH  - Humans
MH  - Interferons/*therapeutic use
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Ribavirin/*therapeutic use
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/genetics
EDAT- 2003/07/23 05:00
MHDA- 2003/09/05 05:00
CRDT- 2003/07/23 05:00
PHST- 2003/07/23 05:00 [pubmed]
PHST- 2003/09/05 05:00 [medline]
PHST- 2003/07/23 05:00 [entrez]
AID - S0002927003003666 [pii]
AID - 10.1111/j.1572-0241.2003.07537.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2003 Jul;98(7):1621-6. doi: 10.1111/j.1572-0241.2003.07537.x.